<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432021000100128</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v4i10.81</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Mutación FTL3-ITD y su relación con variables hematológicas y clínicas en individuos con Leucemia Mieloide Aguda]]></article-title>
<article-title xml:lang="en"><![CDATA[FTL3-ITD mutation and its relationship with hematological and clinical variables in individuals with Acute Myeloid Leukemia]]></article-title>
<article-title xml:lang="pt"><![CDATA[A mutação FTL3-ITD e sua relação com variáveis hematológicas e clínicas em indivíduos com leucemia mielóide aguda]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calderón Calle]]></surname>
<given-names><![CDATA[Fanny]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prieto Fuenmayor]]></surname>
<given-names><![CDATA[Carem Francelys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<volume>4</volume>
<numero>10</numero>
<fpage>128</fpage>
<lpage>142</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432021000100128&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432021000100128&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432021000100128&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN   Introducción . La Leucemia Mieloide Aguda es la neoplasia hematológica más común, caracterizada por una proliferación incontrolada de células madre hematopoyéticas. La mutación FLT3/ITD se presenta en aproximadamente el 30% de todos los pacientes con ésta patología, se asocia con mayor riesgo de recaída y menor supervivencia. El FLT3-ITD puede usarse como un factor pronóstico de la gravedad de ésta patología, importante para predecir los resultados clínicos en pacientes con LMA.  Objetivo . El objetivo de este estudio fue relacionar la mutación FLT3/ITD con variables hematológicas y clínicas en pacientes diagnosticados con Leucemia Mieloide Aguda atendidos en la Sociedad de Lucha contra el Cáncer (SOLCA) de la ciudad de Cuenca, periodo 2013 -2020.  Métodos . Se obtuvieron los datos a partir de registros secundarios registrados una base de datos del hospital, el universo de la muestra lo constituyeron 63 pacientes, diagnosticados con LMA, se les analizó la mutación FLT3/ITD por PCR Convencional.  Resultados . Se encontró la presencia de la mutación en un 9.5% y una asociación significativamente estadística con alteraciones hematológicas relacionados con niveles de hemoglobina anormal (p=0,037) y ratio 6,63 y LDH elevada en 1,21 veces (p=0,024); recuento elevado de leucocitos y blastos (p=0,031). Los individuos portadores de la mutación se presentó con mayor incidencia en el sexo masculino y grupo etario adulto mediano (45-64 años).  Conclusiones . La literatura internacional afirma que la mutación FLT3/ITD en un importante marcador pronóstico; debido a su baja frecuencia, no se pudo determinar una relación estadísticamente significativa con otras variables clínicas en este estudio.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT   Introduction.  Acute Myeloid Leukemia is the most common hematological neoplasm, characterized by an uncontrolled proliferation of hematopoietic stem cells. The FLT3 / ITD mutation occurs in approximately 30% of all patients with this pathology, it is associated with a higher risk of relapse and lower survival. FLT3-ITD can be used as a poor prognostic factor, important for predicting clinical outcomes in patients with AML.  Objective.  The objective of this study was to characterize the FLT3 / ITD mutation and its relationship with hematological and clinical variables in patients diagnosed with Acute Myeloid Leukemia treated at SOLCA in the city of Cuenca, period 2013-2020.  Methods.  Data were obtained from secondary records in a hospital database, the universe of the sample was made up of 63 patients, diagnosed with AML, and the FLT3 / ITD mutation was analyzed by Conventional PCR.  Results.  The presence of the mutation was found in 9.5% and a statistically significantly association with hematological alterations related to abnormal hemoglobin levels (p = 0.037) and ratio 6.63 and LDH elevated in 1.21 times (p = 0.024); Elevated leukocyte and blast count (p = 0.031). Individuals carrying the mutation had a higher incidence in males and in the middle adult age group (45-64 years). Conclusions. The international literature affirms that the FLT3 / ITD mutation is an important prognostic marker; Due to its low frequency, it was not possible to determine a statistically significant relationship with other clinical variables in our study, for which it is suggested to expand the unirverse of the sample.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO   Introdução.  A Leucemia Mielóide Aguda é a malignidade hematológica mais comum, caracterizada pela proliferação descontrolada de células-tronco hematopoiéticas. A mutação FLT3/ITD está presente em aproximadamente 30% de todos os pacientes com esta patologia, e está associada a um maior risco de recaída e menor sobrevida. O FLT3-ITD pode ser usado como um fator prognóstico para a gravidade desta patologia, importante para prever os resultados clínicos em pacientes com LMA.  Objetivo.  O objetivo deste estudo foi relacionar a mutação FLT3/ITD com variáveis hematológicas e clínicas em pacientes diagnosticados com leucemia mielóide aguda tratados na Sociedade de Luta contra o Câncer (SOLCA) na cidade de Cuenca, período 2013 -202020.  Métodos.  Os dados foram obtidos de registros secundários registrados em um banco de dados hospitalar, o universo da amostra consistiu de 63 pacientes diagnosticados com AML, eles foram analisados para a mutação FLT3/ITD por PCR convencional.  Resultados.  A presença da mutação foi encontrada em 9,5% e uma associação estatística significativa com alterações hematológicas relacionadas a níveis anormais de hemoglobina (p=0,037) e relação 6,63 e LDH elevada em 1,21 vezes (p=0,024); contagem elevada de leucócitos e explosões (p=0,031). Os indivíduos portadores da mutação ocorreram com maior incidência no sexo masculino e na faixa etária média adulta (45-64 anos).  Conclusões. A literatura internacional afirma que a mutação FLT3/ITD em um marcador prognóstico importante; devido a sua baixa freqüência, uma relação estatisticamente significativa com outras variáveis clínicas não pôde ser determinada neste estudo.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Duplicación Interna en Tándem]]></kwd>
<kwd lng="es"><![CDATA[Leucemia Mieloide Aguda]]></kwd>
<kwd lng="es"><![CDATA[Lactato Deshidrogenasa]]></kwd>
<kwd lng="es"><![CDATA[Tirosina quinasa]]></kwd>
<kwd lng="en"><![CDATA[Internal Tandem Duplication]]></kwd>
<kwd lng="en"><![CDATA[Leukemia Myeloid Acute]]></kwd>
<kwd lng="en"><![CDATA[Lactate dehydrogenase]]></kwd>
<kwd lng="en"><![CDATA[Tyrosine kinase]]></kwd>
<kwd lng="pt"><![CDATA[Duplicação Tandem interna]]></kwd>
<kwd lng="pt"><![CDATA[Leucemia mielóide aguda]]></kwd>
<kwd lng="pt"><![CDATA[Desidrogenase láctica]]></kwd>
<kwd lng="pt"><![CDATA[Tirosina quinase]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El Papel de FLT3 como Biomarcador en Leucemia Mieloide Aguda]]></article-title>
<source><![CDATA[Arch Med]]></source>
<year>2018</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lagunas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cortéz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FLT3, NPM1 y C/EBP&#945; as prognosis markers in patients with acute myeloid leukemia.]]></article-title>
<source><![CDATA[Rev Hematol]]></source>
<year>2015</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>152-67</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La biología molecular en el diagnóstico de la leucemia mieloide aguda.]]></article-title>
<source><![CDATA[Rev Cuba Hematol Inmunol Hemoter]]></source>
<year>2019</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Grille]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vales]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Boada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zanella]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio del ratio de FLT3-ITD como factor pronóstico en leucemias agudas mieloides: primeros casos estudiados en Uruguay.]]></article-title>
<source><![CDATA[Rev Médica Urug]]></source>
<year>2016</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>145-51</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishfaq M]]></surname>
<given-names><![CDATA[Malik A]]></given-names>
</name>
<name>
<surname><![CDATA[Faiz M]]></surname>
<given-names><![CDATA[Sheikh I]]></given-names>
</name>
<name>
<surname><![CDATA[Asif]]></surname>
<given-names><![CDATA[Khan M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular Characterization of FLT3 Mutations in Acute Leukemia Patients.]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev.]]></source>
<year>2012</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>4581-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schnittger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bacher]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Haferlach]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alpermann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.]]></article-title>
<source><![CDATA[Genes Chromosomes Cancer]]></source>
<year>2012</year>
<volume>51</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>910-24.</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lagunas]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia mieloide aguda. Una perspectiva de los mecanismos moleculares del cáncer.]]></article-title>
<source><![CDATA[Gac Mex Oncol.]]></source>
<year>2016</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>150-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leyto]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute myeloid leukemia]]></article-title>
<source><![CDATA[Rev Hematol.]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yunus]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Johan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Husin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hussein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia.]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev.]]></source>
<year>2015</year>
<volume>16</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4869-72</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuervo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jaime]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study.]]></article-title>
<source><![CDATA[Arch Med Res.]]></source>
<year>2016</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>172-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gámez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Carlos]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[FLT3 y NPM1 como marcadores moleculares en la leucemia mieloblástica aguda.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahmood]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Altaf]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia]]></article-title>
<source><![CDATA[Pak J Med Sci.]]></source>
<year>2019</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuervo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jaime]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FLT3 domain mutations in acute myelogenous leukemia]]></article-title>
<source><![CDATA[Rev Hematol.]]></source>
<year>2012</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>177-84</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burnatt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Licínio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moraes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the presence of FLT3 gene mutation and association with prognostic factors in adult and pediatric acute leukemia patients.]]></article-title>
<source><![CDATA[Braz J Pharm Sci]]></source>
<year>2017</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallogly]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lazarus]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis]]></article-title>
<source><![CDATA[Ther Adv Hematol.]]></source>
<year>2017</year>
<volume>8</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>245-61</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Alfayez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kadia]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ravandi-Kashani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Daver]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection]]></article-title>
<source><![CDATA[Cancer Manag Res]]></source>
<year>2019</year>
<numero>11</numero>
<issue>11</issue>
<page-range>8817-28</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez A]]></surname>
<given-names><![CDATA[Muskus C]]></given-names>
</name>
<name>
<surname><![CDATA[Torres J]]></surname>
<given-names><![CDATA[Cuéllar]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[Vásquez G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular characterization of FLT3-ITD mutations in Colombian patients with acute myelogenous leukemia.]]></article-title>
<source><![CDATA[Rev Hematol.]]></source>
<year>2013</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>166-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz-Argüelles]]></surname>
<given-names><![CDATA[G,]]></given-names>
</name>
<name>
<surname><![CDATA[Garcés]]></surname>
<given-names><![CDATA[Eisele]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón- Urdaneta]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lutz-Presno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Delgado]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary FMS-like tyrosine kinase 3 (FLT3) mutations in Mexican mestizo patients with de novo acute myelogenous leukemia.]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2012</year>
<numero>13</numero>
<issue>13</issue>
<page-range>177-84</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaich]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sastre]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevalencia de mutaciones flt3 en leucemias mieloblásticas agudas]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucena-Araujo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Benicio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ls.]]></surname>
<given-names><![CDATA[Figueiredo-Ponte]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia]]></article-title>
<source><![CDATA[Ann Hematol]]></source>
<year>2010</year>
<volume>89</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>225-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Labopin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meloni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Esteve]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamad]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission.]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2013</year>
<volume>98</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e12-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nazha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Faderl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pierce]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Daver]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.]]></article-title>
<source><![CDATA[Haematologica.]]></source>
<year>2012</year>
<volume>97</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1242-5</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elyamany]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fadalla]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Albalawi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al Shahrani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al Abdulaaly]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.]]></article-title>
<source><![CDATA[Adv Hematol.]]></source>
<year>2014</year>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gallego]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scopinaro]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevos blancos terapéuticos en leucemia aguda pediatrica: caracterización de las mutaciones del gen FLT3.]]></article-title>
<source><![CDATA[Med Infant.]]></source>
<year>2007</year>
<page-range>116-23</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rezaei]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Arandi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Valibeigi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Haghpanah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khansalar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramzi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics]]></article-title>
<source><![CDATA[Turk J Hematol.]]></source>
<year>2017</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>300-6</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tao S]]></surname>
<given-names><![CDATA[Wang C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen Y]]></surname>
<given-names><![CDATA[Deng Y]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[Shi Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics.]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year>2019</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>6766-4.</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang Q]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Caa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between increased mutation rates in DNMT3A and FLT3-ITD and poor prognosis of patients with acute myeloid leukemia]]></article-title>
<source><![CDATA[Exp Ther Med]]></source>
<year>2019</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>3117-24</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varma]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Varma]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes]]></article-title>
<source><![CDATA[Indian J Pathol Microbiol]]></source>
<year>2008</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fms-like Tyrosine Kinase (FLT) 3 and FLT3 Internal Tandem Duplication in Different Types of Adult Leukemia: Analysis of 147 Patients]]></article-title>
<source><![CDATA[Croat Med J.]]></source>
<year>2008</year>
<volume>49</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>650-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karabacak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Erbey]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bayram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Acipayam]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2010</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>923-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pio]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Parámetros bioquímicos enzimáticos (ALT, AST, ALP, &#947;-GT, LDH) en niños con leucemia linfoblástica aguda antes del tratamiento antineoplásico]]></article-title>
<source><![CDATA[Horiz Méd Lima.]]></source>
<year>2015</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>52-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
